Search results for "Lymphocyte"

showing 10 items of 2280 documents

Lymphokine activated killer cells.

1989

Various subpopulations of human leukocytes may be induced by lymphokines to exert cytotoxic activity. In man major histocompatibility complex non-restricted tumor cell lysis by interleukin-2 (IL-2) induced peripheral blood lymphocytes is attributed mainly to natural killer cells. These T cell receptor negative large granular lymphocytes are called lymphokine activated killer (LAK) cells. In order to explore the potential of LAK cells in tumor therapy, several clinical studies have been conducted, using IL-2 alone or in combination with ex vivo IL-2-activated peripheral blood lymphocytes. Objective responses have reproducibly been achieved only in renal cell carcinoma and malignant melanoma …

Cytotoxicity ImmunologicLymphokine-activated killer cellTumor-infiltrating lymphocytesmedicine.medical_treatmentLymphokineHematologyGeneral MedicineImmunotherapyBiologyNatural killer T cellMajor histocompatibility complexLymphocyte ActivationTumor antigenKiller Cells NaturalImmunologymedicinebiology.proteinCytotoxic T cellAnimalsHumansInterleukin-2Killer Cells Lymphokine-ActivatedBlut
researchProduct

Impaired Transporter Associated with Antigen Processing (TAP) Function Attributable to a Single Amino Acid Alteration in the Peptide TAP Subunit TAP1

2003

Abstract The heterodimeric peptide transporter TAP belongs to the ABC transporter family. Sequence comparisons with the P-glycoprotein and cystic fibrosis transmembrane conductance regulator and the functional properties of selective amino acids in these ABC transporters postulated that the glutamic acid at position 263 and the phenylalanine at position 265 of the TAP1 subunit could affect peptide transporter function. To define the role of both amino acids, TAP1 mutants containing a deletion or a substitution to alanine at position 263 or 265 were generated and stably expressed in murine and human TAP1−/− cells. The different TAP1 mutants were characterized in terms of expression and funct…

Cytotoxicity ImmunologicMacromolecular SubstancesPhenylalanineImmunologyAntigen presentationGlutamic AcidATP-binding cassette transporterEndoplasmic ReticulumTransfectionCell LineMiceAdenosine TriphosphateATP Binding Cassette Transporter Subfamily B Member 3MHC class IAnimalsHumansImmunology and AllergyATP Binding Cassette Transporter Subfamily B Member 2Sequence DeletionAlaninechemistry.chemical_classificationAntigen PresentationbiologyHistocompatibility Antigens Class I3T3 CellsIntracellular MembranesTransporter associated with antigen processingMolecular biologyPeptide FragmentsCystic fibrosis transmembrane conductance regulatorAmino acidMice Inbred C57BLProtein SubunitsAmino Acid SubstitutionBiochemistrychemistryMutagenesis Site-Directedbiology.proteinATP-Binding Cassette TransportersTAP1Sequence AlignmentProtein BindingT-Lymphocytes CytotoxicThe Journal of Immunology
researchProduct

Virion Antigens Introduced Exogeneously into the Cell Membrane Render Syngeneic Target Cells Susceptible for T Cell-Mediated Cytolysis

1977

Non-infectious sendai virus renders H-2 matched target cells susceptible to the lytic effect of sendai virus immune cytotoxic T lymphocytes. This observation suggests that exogeneous insertion of virion antigen in the membrane of the target cell is sufficient for T cell cytotoxicity. The finding is incompatible with the concept that H-2K or H-2D gene products of the target cells must be altered in their primary structure (pretranslational effect of the virus infection) for T cell-mediated cytolysis to occur.

Cytotoxicity ImmunologicMacrophagesT-LymphocytesvirusesGeneral MedicineBiologybiology.organism_classificationMolecular biologyVirusSendai virusParainfluenza Virus 1 HumanCell membraneMiceCytolysismedicine.anatomical_structureImmune systemAntigenLytic cycleAntibody SpecificityHistocompatibility AntigensMice Inbred CBAmedicineAnimalsCytotoxic T cellAntigens ViralZeitschrift für Immunitätsforschung: Immunobiology
researchProduct

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

2000

Cancer–testis antigen NY-ESO-1 is one of the most immunogenic tumor antigens defined to date. Spontaneous humoral and CD8+ T-cell responses to NY-ESO-1 are detected in 40–50% of patients with advanced NY-ESO-1-expressing tumors. A clinical trial was initiated to study the immunological effects of intradermal vaccination with 3 HLA-A2-binding NY-ESO-1 peptides in 12 patients with metastatic NY-ESO-1-expressing cancers. Seven patients were NY-ESO-1 serum antibody negative, and five patients were NY-ESO-1 serum antibody positive at the outset of the study. Primary peptide-specific CD8+ T-cell reactions and delayed-type hypersensitivity responses were generated in four of seven NY-ESO-1 antibod…

Cytotoxicity ImmunologicMaleAntibodies Neoplasm10050 Institute of Pharmacology and ToxicologyPeptide610 Medicine & healthDiseaseCD8-Positive T-LymphocytesCancer VaccinesAntigenAntigens NeoplasmImmunityTestisHumansMedicineHypersensitivity DelayedAmino Acid Sequencechemistry.chemical_classification1000 MultidisciplinaryMultidisciplinarybusiness.industryMembrane ProteinsProteinsBiological SciencesClinical trialchemistryImmunizationImmunology570 Life sciences; biologyNY-ESO-1PeptidesbusinessCD8
researchProduct

Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.

2015

Abstract Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design: Twenty-seven patients with CEA-expressing carcinomas were recruited: 15 patients with measurable disease (arm-I) and 12 patients without radiological evidence of disease (arm-II). Six intramuscular vaccinations of naked DNA (1 mg/dose) were administered up to week 12. Clinical and immunologic follow-up was up to week 64 or clinical/radiological disease. Results: DOM-specific immune responses demonstrated successful vaccine delivery. All p…

Cytotoxicity ImmunologicMaleCancer ResearchCD8-Positive T-LymphocytesLymphocyte ActivationCancer VaccinesArticleDNA vaccination03 medical and health sciences0302 clinical medicineCarcinoembryonic antigenImmune systemVaccines DNAMedicineHumansAdverse effectbiologybusiness.industryCarcinomaCancermedicine.diseaseCarcinoembryonic AntigenVaccinationOncologyNaked DNA030220 oncology & carcinogenesisImmunologybiology.proteinFemaleAntibodybusinessOligopeptides030215 immunology
researchProduct

H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the hepatitis B virus core gene products.

2000

The function of the secretory core gene product (HBeAg) of the human hepatitis B virus (HBV) is unknown. It has been proposed that this protein may be passed from the mother to her offspring at the perinatal stage where it might induce immune tolerance. In a previous study we have shown that the murine placenta presents an efficient barrier for the HBe protein and that H-2(b) mice born to HBeAg-positive transgenic mothers do not develop tolerance of specific cytotoxic T cells. In the present work we demonstrate that transgenic mice expressing high serum levels of HBeAg secrete only small amounts of this protein into their milk and excrete minute amounts of the viral gene product in their ur…

Cytotoxicity ImmunologicMaleHepatitis B virusT cellvirusesT-LymphocytesMothersMice TransgenicBiologymedicine.disease_causeLymphocyte ActivationImmune toleranceMiceImmune systemVirologymedicineImmune ToleranceCytotoxic T cellAnimalsHepatitis B e AntigensHepatitis B AntibodiesHepatitis B virusMice Inbred BALB CH-2 Antigensvirus diseasesT-Lymphocytes Helper-InducerHepatitis Bmedicine.diseaseHepatitis BVirologydigestive system diseasesPeptide Fragmentsmedicine.anatomical_structureMilkHBeAgAnimals NewbornImmunologyFemaleCD8T-Lymphocytes CytotoxicVirology
researchProduct

T-T cell interactions during cytotoxic T cell responses. IV. Murine lymphoid dendritic cells are powerful stimulators for helper T lymphocytes.

1982

Enriched populations of Ia+ Fc receptor-negative dendritic cells were compared to other cell types for their stimulatory activity in primary mixed lymphocyte reactions to alloantigens and 2,4,6,-trinitrophenylated syngeneic cells. Dendritic cells were 20-100 times more effective than unfractionated splenocytes. A second cell type exhibiting strong stimulatory activity was an Ia+ Fc receptor-positive transiently adherent cell. Both types of stimulatory cells were only effective when able to produce the monokine interleukin 1. Thus glutaraldehyde-fixed cells were not stimulatory unless extraneous interleukin 1 was added. Stimulation of helper cells by either dendritic cells or Ia+ Fc receptor…

Cytotoxicity ImmunologicMaleRosette FormationMice Inbred AT cellT-LymphocytesImmunologyLymphocyte CooperationReceptors FcBiologyInterleukin 21MicemedicineImmunology and AllergyCytotoxic T cellAnimalsAntigens LyLymphocytesAntigen-presenting cellInterleukin 5Interleukin 3Mice Inbred BALB CLymphokine-activated killer cellImmune SeraHistocompatibility Antigens Class IICell biologyMice Inbred C57BLmedicine.anatomical_structureInterleukin 12Mice Inbred CBAInterleukin-2FemaleEuropean journal of immunology
researchProduct

Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H…

1998

The effects of 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 (a cAMP-dependent protein kinase and protein kinase C inhibitor), n-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 (a cAMP- and cGMP-dependent protein kinase inhibitor) and indomethacin (IND, a cyclooxygenase inhibitor) on both the spontaneous metastatic ability of 3LL (Lewis lung carcinoma) tumor cells and anti-tumor host response were studied. The study of tumor progression showed that H-7 and H-8 (2 mg kg(-1) day(-1) , i.p., for 8 days) significantly reduced the mean number of metastases (0.8 +/- 0.2 and 1.0 +/- 0.7, respectively, P0.05) with respect to the number of lung metastases (4.2 +/- 2.1) observed in the con…

Cytotoxicity ImmunologicMalemedicine.medical_specialtymedicine.drug_classIndomethacinCarcinoma Lewis LungMiceInternal medicine1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsCyclooxygenase InhibitorsLymphocytesEnzyme InhibitorsNeoplasm MetastasisCytotoxicityProtein kinase AProtein kinase CPharmacologybiologyLewis lung carcinomaProtein kinase inhibitorIsoquinolinesMice Inbred C57BLEndocrinologyEnzyme inhibitorTumor progressionbiology.proteinCancer researchDisease ProgressionLeukocytes MononuclearCyclooxygenaseCell DivisionNeoplasm TransplantationSpleenEuropean journal of pharmacology
researchProduct

An Ovalbumin Peptide-Specific Cytotoxic T Cell Clone with Antigen Self-Presentation Capacity Uses Two Distinct Mechanisms to Kill Target Cells

1993

Abstract Cloned 10BK.1 T cells with specificity for the ovalbumin peptide OVA257-264 are representative of a novel cell type within the CD8 + subset of T cells. In the presence and in the absence of added antigen presenting cells these T cells react toward antigen (Ag) by proliferation and lymphokine production. These data suggest self-presentation of the Ag by 10BK.1 cells. Here we present evidence that 10BK.1 cells exhibit cytotoxic activity that involves two different cytotoxic effector mechanisms. (i) One mechanism is fast killing activity, apparent within 4 hr. Constitutive mouse T cell-specific proteinase-1 (MTSP-1) activity, constitutive expression of MTSP-1 RNA, increased by Ag chal…

Cytotoxicity ImmunologicPore Forming Cytotoxic ProteinsOvalbuminImmunologyAntigen presentationAntigen-Presenting CellsBiologyCytoplasmic GranulesLymphocyte ActivationGranzymesCell LineMiceInterleukin 21AntigenAnimalsCytotoxic T cellIL-2 receptorAntigen-presenting cellLymphotoxin-alphaMembrane GlycoproteinsCD40PerforinTumor Necrosis Factor-alphaSerine EndopeptidasesDegranulationMolecular biologyClone Cellsbiology.proteinInterleukin-2T-Lymphocytes CytotoxicCellular Immunology
researchProduct

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

1994

A number of cytolytic T lymphocyte (CTL) clones derived from several melanoma patients have been found to recognize a majority of melanomas from HLA-A2 patients. We have reported previously that two such CTL clones recognize a product of the tyrosinase gene that is presented by HLA-A2. Here we show that one of these CTL clones recognizes a peptide encoded by the first nine amino acids of the putative signal sequence of tyrosinase. The other CTL clone recognizes a different tyrosinase peptide corresponding to amino acids 368-376. Both peptides contain consensus motifs of HLA-A2 binding peptides.

Cytotoxicity ImmunologicSignal peptideTyrosinaseMolecular Sequence DataImmunologyClone (cell biology)Tyrosinase PeptidePeptideIn Vitro TechniquesBiologyHLA-A2 AntigenTumor Cells CulturedConsensus sequenceHumansImmunology and AllergyAmino Acid SequenceMelanomaPeptide sequenceDNA Primerschemistry.chemical_classificationBase SequenceMonophenol MonooxygenaseVirologyRecombinant ProteinsCTL*chemistryPeptidesT-Lymphocytes CytotoxicEuropean Journal of Immunology
researchProduct